The Leukemia & Lymphoma Society has awarded separate grants to researchers at Harvard Medical School and University of Cambridge as part of its ongoing efforts to facilitate lifesaving research.

The awards, formally known as Marshall A. Lichtman Specialized Center of Research (SCOR) grants, are both valued at $1.25 million per year for up to five years. SCOR is a research grant program that has generated more than $235 million of funding since 2000. The program facilitates collaborative efforts among leading researchers to produce new therapies for leukemia, lymphoma and myeloma.

Harvard’s recipient, Dr. Frederick W. Alt., is engaged in research to learn how B cell lymphomas develop and formulate new therapies to “eliminate these malignant cells.” In addition, Cambridge’s Dr. Anthony Green’s research involves patients with myeloproliferative neoplasms (MPNs). His project, “Genome-Wide Analysis of Drug Response in the Myeloproliferative Neoplasms,” addresses defects in the JAK2 gene that are closely associated with MPNs and affect roughly 200,000 people in the U.S.